Bausch Health Companies

BHC · TORONTO

$6.42+$0.10 (+1.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.32

BHC analyst rating

HoldConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform0
Sell0

12-month price target · 2 analysts

Average $6.45 (+0.5% upside)

Low: $6.39
Now: $6.42
High: $6.64

Upgrades and downgrades

The latest rating actions, newest first

BHC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Apr 27, 2026	Maintains	Sector Perform	$10.00 → $9.00	56%
Barclays	Feb 25, 2026	Maintains	Equal-Weight	$8.00 → $7.00	53%
Truist Securities	Jan 7, 2026	Maintains	Hold	$7.00 → $8.00	59%
Barclays	Dec 9, 2025	Initiates	Equal-Weight	$8.00	53%

The case for and against

Updated Oct 23, 2025

Bull case

Bausch Health Companies Inc. has demonstrated solid performance across its segments, with diversified product revenues growing 1% year-over-year, exceeding expectations from both RBC and consensus estimates. The company experienced notable growth in its Canadian market, where revenues increased by 9% year-over-year, driven by strong sales of Ryaltris and other promoted products. Additionally, the Solta Medical segment showed exceptional growth of 28% year-over-year and 33% on an organic basis, surpassing analyst projections and signaling robust demand within this sector.

Bear case

Bausch Health Companies Inc. is facing a challenging financial landscape, as evidenced by a -1% year-over-year decline in international revenues, which fell short of consensus expectations. Notably, the Latin America region experienced a significant revenue drop of -14% year-over-year, highlighting vulnerability to fluctuations in foreign exchange and government tender timing. Additionally, projections indicate a concerning 7% year-over-year revenue decline by 2027, attributable to unquantified headwinds from the Inflation Reduction Act (IRA), further suggesting ongoing operational challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.